Clinical Trials
3 trialsNCT05607420 2025-08-24
NatHaLi-01
Cellectis S.A.
Phase 1/2 Recruiting
NCT01030900 2022-10-06
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00038883 2018-11-07
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase NA Terminated